FIGURE 1.
FIGURE 2.
Incidence and grade of major adverse reactions in the ANL group and ANL+ S-1 group
| Adverse reactions | Group ANL (n=22) | Group ANL+S-1 (n=22) | x2 | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any level | 1 | 2 | 3/4 | Any level | 1 | 2 | 3/4 | |||
| Hypertension | 11(50.0%) | 7 | 2 | 2 | 12(54.5%) | 6 | 3 | 3 | 0.910 | 0.763 |
| Anorexia | 5(22.7%) | 4 | 1 | 0 | 8(36.4%) | 5 | 3 | 0 | 0.983 | 0.322 |
| Fatigue | 16(72.7%) | 14 | 2 | 0 | 18(81.8%) | 16 | 2 | 0 | 0.518 | 0.472 |
| Hand-foot-skin reaction | 5(22.7%) | 3 | 1 | 1 | 7(31.8%) | 4 | 3 | 0 | 0.458 | 0.498 |
| Leucopenia | 3(13.6%) | 2 | 1 | 0 | 4(18.2%) | 3 | 1 | 0 | 0.170 | 0.680 |
| Bleeding | 1(4.5%) | 0 | 1 | 0 | 0(0.0%) | 0 | 0 | 0 | 0.410 | 0.235 |
| ALT abnormal | 6(27.3%) | 6 | 0 | 0 | 8(36.4%) | 7 | 1 | 0 | 0.419 | 0.517 |
| Oral mucositis | 3(13.6%) | 1 | 2 | 0 | 5(22.7%) | 3 | 2 | 0 | 0.617 | 0.432 |
| Hypothyroidism | 6(27.3%) | 4 | 2 | 0 | 6(27.3%) | 5 | 1 | 0 | 0.000 | 1.000 |
| Diarrhea | 1(4.5%) | 0 | 0 | 1 | 2(9.1%) | 1 | 1 | 0 | 0.364 | 0.546 |
Baseline characteristics of the ANL group and ANL+S-1 group were compared
| Group ANL n=27 | Group ANL+S-1 n=27 | x2 | P | |
|---|---|---|---|---|
| Gender n % | ||||
| Male | 23(85.2) | 22(81.5) | 0.133 | 0.715 |
| Female | 4(14.8) | 5(18.5) | ||
| Age median | 54 | 56 | ||
| ECOG PS n % | 0.912 | 0.340 | ||
| 1 | 8(29.6) | 5(18.5) | ||
| 2 | 19(70.4) | 22(81.5) | ||
| Child-Pugh, n % | 0.078 | 0.780 | ||
| A grade | 10(37.0) | 11(40.7) | ||
| B grade ≤ 7 | 17(63.0) | 16(59.3) | ||
| Stages (BCLC), n % | ||||
| C | 27(100.0) | 27(100.0) | ||
| AFP n % | 0.318 | 0.573 | ||
| AFP ≥ 400 ng/mL | 16(59.3) | 18(66.7) | ||
| AFP < 400 ng/mL | 11(40.7) | 9(33.3) | ||
| HBV DNA n % | 1.421 | 0.233 | ||
| ≥ 1.0 × 103 IU/mL | 6(22.2) | 10(37.0) | ||
| < 1.0 × 103 IU/mL | 21(77.8) | 17(63.0) | ||
| PVTT n % | 0.092 | 0.761 | ||
| PV1–3 | 18(66.7) | 16(59.3) | ||
| PV4 | 2(7.4) | 3(11.1) | ||
| EHS n % | 9(33.3) | 7(25.9) | 0.355 | 0.551 |